Compare iShares Core Growth Allocation ETF (AOR) vs Illumina, Inc. (ILMN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
iShares Core Growth Allocation ETF vs Illumina, Inc. — how do they compare? iShares Core Growth Allocation ETF trades at $69.09, while Illumina, Inc. trades at $189.67 (market cap $28.78B). Which is the better fit depends on your goals.
| AOR | ILMN | |
|---|---|---|
52-Week High | $69.85 | $194.33 |
52-Week Low | $61.00 | $91.00 |
Market Cap | — | $28.78B |
Sector | — | Health |
Enterprise Value | — | $30.17B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
The iShares Core Growth Allocation ETF (AOR) trades at $69.10, up 0.25% on the day, with a bearish technical signal from moving averages and neutral oscillators. The fund maintains a fixed 60/40 stock/bond allocation, rebalanced semiannually, with a low 0.20% expense ratio. Recent news highlights its role as a core holding but notes underperformance versus the S&P 500 over a decade.
Outlook: AOR offers diversified, low-cost exposure but faces headwinds from equity-bond correlation shifts. Risks include interest rate sensitivity and competition from pure equity funds. Analyst sentiment is mixed, balancing simplicity against relative returns.
Illumina (ILMN) trades at $190.20, down 1.84% on the day but up significantly year-to-date with strong momentum. The stock shows bullish technical signals with moving averages supporting upward trends, while fundamentals reflect a turnaround with net income reaching $850 million in 2025 after previous losses. Recent news highlights product launches and leadership appointments, with the company scheduled to report Q2 2026 earnings on July 30, 2026.
The outlook remains positive with analyst consensus leaning bullish, though valuation multiples appear elevated. Key risks include competitive pressure from new entrants like Roche's Axelios sequencer and execution challenges in maintaining profitability growth. The upcoming earnings report will be critical for validating the current rally's sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Core Growth Allocation ETF
The fund is a fund of funds and seeks its investment objective by investing primarily in underlying funds that themselves seek investment results corresponding to their own respective underlying indexes. It generally will invest at least 80% of its assets in the component securities of its underlying index. The index measures the performance of the S&P Dow Jones Indices LLC proprietary allocation model.
Read more on AOR →About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →
